ELI LILLY AND COMPANY Total Contract Liability
ELI LILLY AND COMPANY (LLY) had Total Contract Liability of $166.30 million as of 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2025-02-19
- 2024-12-31: Contract with Customer, Liability $166.30M.
- 2024-09-30: Contract with Customer, Liability $173.20M.
- 2024-06-30: Contract with Customer, Liability $180.10M.
- 2024-03-31: Contract with Customer, Liability $186.70M.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2024-12-31 | $166.30M 10-K · filed 2025-02-19 | |
| 2024-09-30 | $173.20M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $180.10M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $186.70M 10-Q · filed 2024-04-30 | |
| 2023-12-31 | $193.60M 10-K · filed 2025-02-19 | |
| 2023-09-30 | $200.70M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $211.10M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $220.30M 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $219.20M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $232.50M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $242.10M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $251.60M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $262.60M 10-K · filed 2023-02-22 | |
| 2021-09-30 | $278.40M 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $270.90M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $346.60M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $276.80M 10-K · filed 2022-02-23 | |
| 2020-09-30 | $289.50M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $299.80M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $307.80M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $264.60M 10-K · filed 2021-02-17 | |
| 2019-09-30 | $272.30M 10-Q · filed 2019-10-25 | |
| 2019-06-30 | $277.60M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $286.40M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $294.90M 10-K · filed 2020-02-19 | $299.30M 10-K · filed 2019-02-19 |
| 2018-09-30 | $308.60M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $315.70M 10-Q · filed 2018-07-25 | |
| 2018-03-31 | $324.50M 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $330.90M 8-K · filed 2019-10-24 | $335.20M 10-Q · filed 2018-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |